Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Non-Final OA | GENZYME CORPORATION |
| 17916664 | AFFINITY MATURED ANTI-LAP ANTIBODIES AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18182323 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18077139 | Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18364185 | ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF | Final Rejection | Genentech, Inc. |
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | Non-Final OA | Genentech, Inc. |
| 17775257 | METHOD OF TREATING OR AMELIORATING CUSHING'S SYNDROME USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | Non-Final OA | AMGEN INC. |
| 19259540 | SLIDING BIOACTIVE PEPTIDES FOR THERAPEUTIC DELIVERY | Non-Final OA | Northwestern University |
| 18040260 | CD45 BINDING MOLECULES AND METHODS OF USE | Non-Final OA | Synthekine, Inc. |
| 18054284 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES | Final Rejection | Eli Lilly and Company |
| 17408937 | TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | Final Rejection | Sanofi |
| 18154020 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Final Rejection | Janssen Pharmaceutica NV |
| 18262548 | ELECTROTRANSFER METHODS FOR TREATING TUMORS | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18312194 | NANOPARTICLE VACCINES AND USES THEREOF FOR PROPHYLAXIS AND TREATMENT OF ATHEROSCLEROSIS USING PEPTIDE 210 AS AN ANTIGEN | Non-Final OA | University of Southern California |
| 18014449 | Wound Healing Composition and Uses Thereof | Non-Final OA | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 18023120 | ANTI-VEGF HEXAMERIC ANTIBODY AND COMPOSITION COMPRISING SAME | Final Rejection | MEDYTOX INC. |
| 18541602 | CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 17815468 | Lysosomal Targeting Peptides and Uses Thereof | Non-Final OA | BIOMARIN PHARMACEUTICAL INC. |
| 17829620 | Lysosomal Targeting Peptides and Uses Thereof | Non-Final OA | BIOMARIN PHARMACEUTICAL INC. |
| 17996557 | LONG-ACTING ANTI-IL31 ANTIBODIES FOR VETERINARY USE | Non-Final OA | Elanco US Inc. |
| 18007606 | ANTI-IGF-1 RECEPTOR HUMANIZED ANTIBODY | Non-Final OA | Teijin Pharma Limited |
| 18151305 | MATERIALS AND METHODS OF IL-1BETA BINDING PROTEINS | Non-Final OA | JOHNSON & JOHNSON ENTERPRISE INNOVATION INC. |
| 18458214 | Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders | Non-Final OA | Universitat De Barcelona |
| 17625380 | MAGEA10 SPECIFIC T CELL RECEPTORS AND THEIR USE | Non-Final OA | MEDIGENE IMMUNOTHERAPIES GMBH |
| 18008093 | ANTI-HBV ANTIBODIES AND METHODS OF USE | Non-Final OA | Institut Pasteur |
| 17767620 | MODULATING INTERLEUKIN-10 SIGNALING TO BOOST HEALING IN DIABETIC WOUNDS | Final Rejection | Rush University Medical Center |
| 17242793 | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS | Non-Final OA | UMC Utrecht Holding B.V. |
| 18245563 | BINDING PROTEINS AND ANTIGEN BINDING FRAGMENTS THEREOF THAT BIND ABETA | Non-Final OA | Merck Sharpe & Dohme LLC |
| 17739457 | METHODS AND COMPOSITIONS FOR PDGF-CC INHIBITION | Final Rejection | Paracrine Therapeutics AB |
| 17801108 | ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR USE IN THERAPY OR PREVENTION OF SHOCK | Final Rejection | ADRENOMED AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy